Advertisement
Advertisement
U.S. markets open in 7 hours 45 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NeoGenomics, Inc. (NEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.66-0.26 (-2.91%)
At close: 04:00PM EDT
8.30 -0.36 (-4.16%)
After hours: 06:10PM EDT
Advertisement

NeoGenomics, Inc.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
239 768 0600
https://www.neogenomics.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees2,000

Key Executives

NameTitlePayExercisedYear Born
Mr. George A. CardozaPres & COO of Lab Operations800.5kN/A1962
Ms. Kathryn B. McKenzieChief Sustainability & Risk Officer793.48k128.7k1984
Mr. Christopher Michael Smith BScCEO & DirectorN/AN/A1963
Mr. William Bishop BonelloChief Financial OfficerN/AN/A1965
Ms. Cynthia J. DieterChief Accounting OfficerN/AN/A1975
Mr. John MooneyChief Technology OfficerN/AN/AN/A
Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D.Pres of Lab Operations & Chief Scientific OfficerN/AN/AN/A
Charlie EidsonDirector of Investor Relations and Corp. Devel.N/AN/AN/A
Mr. Hutan Hashemi J.D.Chief Compliance OfficerN/AN/AN/A
Ms. Ali OlivioGen. Counsel & Corp. Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Corporate Governance

NeoGenomics, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement